{"title": "Seguridad precl\u00ednica de la vacuna Quimi-Hib\u00ae adyuvada con fosfato de aluminio durante el desarrollo del producto", "author": "Dania Bacard\u00ed; Karelia Cosme; Lizet Aldana; Nelson Merino; Jos\u00e9 Su\u00e1rez; Omar Mosqueda; Dioslaida Urquiza; Juan Romero; Roberto Madrigal; Rub\u00e9n Amaya; Lourdes Hern\u00e1ndez", "url": null, "hostname": null, "description": null, "sitename": "Biotecnolog\u00eda Aplicada", "date": "2009-09-01", "id": null, "license": null, "body": null, "comments": "", "commentsbody": null, "raw_text": null, "text": "2013, N\u00famero 2\nBiotecnol Apl 2013; 30 (2)\nSeguridad precl\u00ednica de la vacuna Quimi-Hib\u00ae adyuvada con fosfato de aluminio durante el desarrollo del producto\n[ ](addFavorito.php?idArt=48188&idPub=4953)\nBacard\u00ed D, Cosme K, Aldana L, Merino N, Su\u00e1rez J, Mosqueda O, Urquiza D, Romero J, Madrigal R, Amaya R, Hern\u00e1ndez L\nIdioma: Espa\u00f1ol\nReferencias bibliogr\u00e1ficas: 22\nPaginas: 111-124\nArchivo PDF: 267.21 Kb.\nRESUMEN\nHaemophilus influenzae\ntipo b (Hib) es una bacteria gramnegativa causante de enfermedades como meningitis,\nneumon\u00eda, epiglotitis, celulitis, septicemia, artritis, entre otras, en los seres humanos. La meningitis causada por Hib es muy grave, con una tasa de muertes de m\u00e1s del 50 % en varias partes del mundo. Por tales razones, la obtenci\u00f3n de una vacuna contra esta afecci\u00f3n es una prioridad. El objetivo de este estudio fue evaluar la seguridad precl\u00ednica\nde la vacuna Quimi-Hib\u00ae\n(ant\u00edgeno sint\u00e9tico de Hib conjugado con toxoide tet\u00e1nico), en una formulaci\u00f3n adyuvada con fosfato de aluminio, durante la etapa de desarrollo del producto. Los ensayos toxicol\u00f3gicos incluyeron estudios de toxicidad aguda (15 d\u00edas), de tolerancia local (30 d\u00edas) y de toxicidad a dosis repetidas (15 d\u00edas), que incluyeron la dosis terap\u00e9utica de la vacuna. Se exploraron tres niveles de dosis de la vacuna y un placebo (excipientes m\u00e1s adyuvante), que se administraron por v\u00eda intramuscular a ratas Sprague Dawley de ambos sexos. Seg\u00fan nuestros resultados en el espectro de dosis explorado en las ratas, se concluy\u00f3 que la vacuna conjugada Quimi-Hib\u00ae\nadyuvada en fosfato de aluminio no es t\u00f3xica, ni provoca efectos sist\u00e9micos adversos en esa especie. No se detectaron alteraciones macrosc\u00f3picas en los \u00f3rganos estudiados, y al evaluar el sitio de administraci\u00f3n, solo se observaron induraciones causadas por granulomas macrof\u00e1gicos, resultantes del mecanismo de acci\u00f3n del adyuvante incluido en la formulaci\u00f3n.\nREFERENCIAS (EN ESTE ART\u00cdCULO)\nRobbins JB, Schneerson R. Haemophilus influenzae type b: the search for a vaccine. Pediatr Infect Dis J. 1987;6(8):791-4.\nAhmed N, Gottschalk S. How to design effective vaccines: lessons from an old success story. Expert Rev Vaccines. 2009; 8(5):543-6.\nOsterholm MT, Kelley NS, Sommer A, Belongia EA. Effi cacy and effectiveness of infl uenza vaccines: a systematic review and meta-analysis. Lancet Infect Dis. 2012; 12(1):36-44.\nFitzwater SP, Watt JP, Levine OS, Santosham M. Haemophilus influenzae type b conjugate vaccines: considerations for vaccination schedules and implications for developing countries. Hum Vaccines. 2010;6(10):810-8.\nPeltola H. Worldwide Haemophilus influenzae type b disease at the beginning of the 21st century: global analysis of the disease burden 25 years after the use of the polysaccharide vaccine and a decade after the advent of conjugates. Clin Microbiol Rev. 2000;13(2):302-17.\nPlotkin SA. Correlates of protection induced by vaccination. Clin Vaccine Immunol. 2010;17(7):1055-65.\nVerez-Bencomo V, Fernandez-Santana V, Hardy E, Toledo ME, Rodriguez MC, Heynngnezz L, et al. A synthetic conjugate polysaccharide vaccine against Haemophilus influenzae type b. Science. 2004; 305(5683):522-5.\nEuropean Medicines Agency. CPMP/ SWP/465/95. Note for guidance on preclinical pharmacological and toxicological testing of vaccines (CPMP adopted Dec 97). London: EMA; 1997 (cited 2012 Apr 16). Available from: http://www.ema.europa. eu/docs/en_GB/document_library/Scientifi c_guideline/2009/10/WC500004004. pdf\nEuropean Medicines Agency. CPMP/ SWP/1042/99. Note for guidance on repeated dose toxicity (CPMP adopted July 2000). London: EMA cited 2012 Apr 16). Available from: http://www.ema.europa. eu/docs/en_GB/document_library/Scientifi c_guideline/2009/09/WC500003102. pdf\nEuropean Medicines Agency. CPMP/ ICH/286/95. Note for guidance on Nonclinical safety studies for the conduct of Human clinical trials for pharmaceuticals. ICH M3 (R2). 2008. Available from: http://www. ema.europa.eu/docs/en_GB/document_ library/Scientific_guideline/2009/09/ WC500002941.pdf\nDiehl KH, Hull R, Morton D, Pfi ster R, Rabemampianina Y, Smith D, et al. A good practice guide to the administration of substances and removal of blood, including routes and volumes. J Appl Toxicol. 2001;21(1):15-23.\nCosme K. Programa para el Uso de Animales de Experimentaci\u00f3n del Centro de Ingenier\u00eda Gen\u00e9tica y Biotecnolog\u00eda. Edici\u00f3n 01;1998.\nVan Zutphen LFM, Balls M . Animal Alternatives, Welfare and Ethics. Developments in Animal and Veterinary Sciences. Amsterdam: Elsevier Science Ltd.; 1997.\nOlfert ED, Cross BM, Mc William A. Guide to the care and use of experimental animals. 2nd ed. Ontario: Canadian Council on Animal Care; 1998.\nHarkness JE, Wagner JE. The Biology and Medicine of Rabbits and Rodents. 4th ed. Philadelphia, PA: Lea and Febiger; 1995.\nLindblad EB. Aluminium adjuvants-in retrospect and prospect. Vaccine. 2004; 22(27-28):3658-68.\nGupta RK. Aluminum compounds as vaccine adjuvants. Adv Drug Deliv Rev. 1998;32(3):155-72.\nHarandi AM, Medaglini D, Shattock RJ. Vaccine adjuvants: a priority for vaccine research. Vaccine. 2010;28(12):2363-6.\nChong H, Brady K, Metze D, Calonje E. Persistent nodules at injection sites (aluminium granuloma) - clinicopathological study of 14 cases with a diverse range of histological reaction patterns. Histopathology. 2006;48(2):182-8.\nBordet AL, Michenet P, Cohen C, Arbion F, Ekindi N, Bonneau C, et al. Granulome post-vaccinal li\u00e9 \u0155 l\u2019hydroxyde d\u2019aluminium. Ann Pathol. 2001;21(2): 149-52.\nMakwana N, Riordan FA. Bacterial meningitis: the impact of vaccination. CNS Drugs. 2007;21(5):355-66.\nGoto N, Kato H, Maeyama J, Shibano M, Saito T, Yamaguchi J, et al. Local tissue irritating effects and adjuvant activities of calcium phosphate and aluminium hydroxide with different physical properties. Vaccine. 1997;15(12-13):1364-71.", "language": null, "image": null, "pagetype": null, "links": ["https://www.medigraphic.com/", "resumenI.cgi?IDARTICULO=48188", "#", "https://www.medigraphic.com/cgi-bin/new/publicaciones.cgi?IDREVISTA=281", "https://www.medigraphic.com/cgi-bin/new/contenido.cgi?IDPUBLICACION=4953", "https://www.medigraphic.com/cgi-bin/new/publicaciones.cgi?IDREVISTA=281", "#", "https://www.medigraphic.com/cgi-bin/new/informacion.cgi?IDREVISTA=281", "https://www.medigraphic.com/cgi-bin/new/directorio.cgi?IDREVISTA=281", "#", "https://www.medigraphic.com/cgi-bin/new/instrucciones.cgi?IDREVISTA=281", "https://www.medigraphic.com/", "https://www.medigraphic.com/", "https://www.medigraphic.com/cgi-bin/new/medigraphic.cgi", "#", "#", "#", "#", "addFavorito.php?idArt=48188&idPub=4953", "https://www.medigraphic.com/pdfs/biotecapl/ba-2013/ba132e.pdf", "#", null, null, null, null, null, null, null, null, null, null, null, null, null, null, null, null, null, null, null, null, null, null, null]}